Dmitry Balyasny Balyasny Asset Management
Dmitry Balyasny is the founder of Balyasny Asset Management, a major multi-strategy and multi-manager hedge fund platform. The firm allocates capital across fundamental equities, macro, quant, and other teams under a central risk framework. Balyasny’s platform is often cited alongside other leading pod-shop multi-strategy firms.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$509M |
| 2 |
Mastercard
MA
|
+$404M |
| 3 |
SCHW
Charles Schwab
SCHW
|
+$401M |
| 4 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$302M |
| 5 |
Intuit
INTU
|
+$277M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Arthur J. Gallagher & Co
AJG
|
+$416M |
| 2 |
Coca-Cola
KO
|
+$394M |
| 3 |
Starbucks
SBUX
|
+$374M |
| 4 |
Salesforce
CRM
|
+$351M |
| 5 |
PNC Financial Services
PNC
|
+$268M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 10.34% |
| 2 | Financials | 9.88% |
| 3 | Consumer Discretionary | 8.94% |
| 4 | Industrials | 7.09% |
| 5 | Healthcare | 6.66% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SNCY
2576
DELISTED
Sun Country Airlines
SNCY
| $192K | ﹤0.01% |
15,600
+3,300
| +27% | +$51.1K |
|
2577
Digital Turbine
APPS
$1.3B
| $191K | ﹤0.01% |
+70,290
| New | +$228K |
|
2578
Xeris Biopharma Holdings
XERS
$1.59B
| $189K | ﹤0.01% |
34,454
+17,301
| +101% | +$69.8K |
|
2579
Shore Bancshares
SHBI
$775M
| $189K | ﹤0.01% |
+13,960
| New | +$210K |
|
|
LOGC
2580
DELISTED
ContextLogic
LOGC
| $188K | ﹤0.01% |
26,983
+12,128
| +82% | +$90.3K |
|
2581
Hertz
HTZ
$781M
| $187K | ﹤0.01% |
47,465
+32,385
| +215% | +$130K |
|
2582
Annexon
ANNX
$959M
| $187K | ﹤0.01% |
+96,752
| New | +$322K |
|
2583
Western New England Bancorp
WNEB
$278M
| $185K | ﹤0.01% |
19,931
+8,206
| +70% | +$75.7K |
|
2584
Microvast
MVST
$298M
| $185K | ﹤0.01% |
+157,842
| New | +$274K |
|
2585
Xilio Therapeutics
XLO
$60.5M
| $184K | ﹤0.01% |
18,168
-6,348
| -26% | -$79.8K |
|
2586
Corvus Pharmaceuticals
CRVS
$1.19B
| $184K | ﹤0.01% |
57,827
+9,492
| +20% | +$44.7K |
|
2587
AbCellera Biologics
ABCL
$3.44B
| $181K | ﹤0.01% |
81,083
+67,562
| +500% | +$194K |
|
|
TECX
2588
Tectonic Therapeutic
TECX
$713M
| $181K | ﹤0.01% |
10,192
-236,808
| -96% | -$7.72M |
|
2589
FinWise Bancorp
FINW
$192M
| $180K | ﹤0.01% |
+10,289
| New | +$184K |
|
2590
Inhibikase Therapeutics
IKT
$349M
| $178K | ﹤0.01% |
+81,161
| New | +$204K |
|
2591
Vuzix
VUZI
$235M
| $176K | ﹤0.01% |
86,322
+50,923
| +144% | +$167K |
|
2592
Takeda Pharmaceutical
TAK
$58.2B
| $175K | ﹤0.01% |
11,773
-181,430
| -94% | -$2.54M |
|
2593
Hafnia
HAFN
$4.06B
| $175K | ﹤0.01% |
41,995
-15,990
| -28% | -$79.2K |
|
2594
Security National Financial
SNFCA
$229M
| $174K | ﹤0.01% |
+15,857
| New | +$180K |
|
|
BORR
2595
Borr Drilling
BORR
$1.35B
| $173K | ﹤0.01% |
+78,778
| New | +$237K |
|
2596
American Outdoor Brands
AOUT
$142M
| $171K | ﹤0.01% |
+14,077
| New | +$216K |
|
|
NEXN
2597
Nexxen International
NEXN
$557M
| $170K | ﹤0.01% |
+20,405
| New | +$184K |
|
2598
Blue Ridge Bankshares
BRBS
$352M
| $170K | ﹤0.01% |
52,091
+21,008
| +68% | +$71.8K |
|
2599
Agilon Health
AGL
$1.57B
| $170K | ﹤0.01% |
+1,567
| New | +$136K |
|
2600
ImmunityBio
IBRX
$8.03B
| $169K | ﹤0.01% |
+56,165
| New | +$170K |
|
Similar funds
Dmitry Balyasny's Q1 2025 Portfolio in Review
As of Q1 2025, Dmitry Balyasny held 3,423 positions worth $60.5B, down 9.9% from $67.1B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Dmitry Balyasny withdrew a net $4.05B in Q1 2025, closing 697 positions and reducing 920 holdings. Its most notable exit was Starbucks, an estimated $374M position sold in full.
By sector, the portfolio is most concentrated in Technology at 10% of assets, up from 10% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Dmitry Balyasny opened a new position in AutoZone worth $255M.
- Dmitry Balyasny's largest Q1 2025 buy was AutoZone: 66,934 shares worth $255M.
- Dmitry Balyasny added most to iShares Core S&P 500 ETF in Q1 2025, an estimated $509M increase.
- Dmitry Balyasny's biggest Q1 2025 reduction was Arthur J. Gallagher & Co, cutting an estimated $416M.
- Dmitry Balyasny fully exited Starbucks in Q1 2025, selling an estimated $374M.
- Dmitry Balyasny's ten largest holdings make up 13% of its $60.5B portfolio in Q1 2025.
- Dmitry Balyasny opened 759 new positions and closed 697 in Q1 2025.
- Dmitry Balyasny's portfolio value fell 9.9% quarter-over-quarter to $60.5B.
Based on Balyasny Asset Management's 13F filing for Q1 2025, filed 15 May 2025.